Plasmin, a directly acting thrombolytic agent, demonstrated a very favorable safety profile upon intra-arterial delivery to the clot site; however, its thrombolytic efficacy remains to be further assessed. In this study, differences in thrombolysis between clots exposed to equimolar concentrations of plasmin and recombinant tissue-type plasminogen activator (rt-PA) after partial vessel recanali...

OBJECTIVE This study aims to compare the clot stabilization on root surfaces conditioned with citric acid and ethylenediamine-tetraacetic acid (EDTA). MATERIALS AND METHODS Scaled root samples (n = 100) were set in fve groups: group I-control group (saline solution); group II (24% EDTA); group III (25% citric acid); group IV (EDTA + citric acid); group V (citric acid + EDTA). Fifty samples we...

Rivaroxaban (Figure 1) is a new oral prescription medication used to help prevent clots from forming. Rivaroxaban is marketed under the brand name Xarelto, and it is approved in the United States, Canada, and Europe to prevent blood clots in patients undergoing an elective hip or knee replacement and to prevent stroke from atrial fibrillation. This Cardiology Patient Page will discuss the use o...

BACKGROUND Recombinant activated factor VII (rFVIIa) is currently administered off-label to control diffuse coagulopathic bleeding of patients with traumatic injuries. These patients are often cold, acidotic, and coagulopathic upon arrival and each responds differently to rFVIIa therapy. This study investigated the effects of hypothermia on clotting and the potential benefit of rFVIIa administr...

It is now scientifically well established that inflammation plays a role in the initiation, growth and destabilization of atherosclerotic plaques that lead to clogged arteries and most heart attacks. The rupture of unstable, cholesterol-filled plaques triggers the formation of a blood clot inside the artery that can suddenly block blood flow to tissues down stream from that clot.[1] [2] [3] Inf...

Following an injury to the walls of a blood vessel, platelet aggregation and blood coagulation are induced. Through a series of enzymatic and biochemical interactions, a blood clot is formed. Using ordinary differential equations with mass action and Michaelis-Menton kinetics to describe these interactions and computer programs like Fortran and Matlab, we are able to model blood clot formation ...

Factor XIII or "fibrin-stabilizing factor," is a transglutaminase circulates in the blood circulation as a hetero tetramer with two catalytic A subunits and two carrier B subunits. This important coagulation factor has a crucial role in clotting cascade and produces strong covalent bonds between soluble formed fibrin monomers during coagulation. This stable cross linked fibrin strands are resis...

BACKGROUND AND PURPOSE We studied in monkeys why vasospasm resolves after subarachnoid hemorrhage (SAH). METHODS Monkeys underwent angiography and right (n=17) or bilateral (n=8) SAH. Animals with bilateral SAH underwent angiography 1, 3, 5, and 7 days later. Animals with right SAH underwent angiography 7 days later. The clot was then not removed (n=5), removed and replaced with fresh clot (n...

BACKGROUND Thrombelastography (TEG) is suggested as an optimal instrument for the identification of acute traumatic coagulopathy-induced alterations in coagulation status. Patient whole blood (WB) used in TEG analysis is generally collected from a large blood vessel containing representative systemic blood, often close to 40% hematocrit (Hct). Trauma patients often exhibit bleeding from the mic...

Here we report the first application of a fractal analysis of the viscoelastic properties of incipient blood clots. We sought to ascertain whether the incipient clot’s fractal dimension, Df, could be used as a functional biomarker of hemostasis. The incipient clot is formed at the gel point (GP) of coagulating blood, the GP demarcating a functional change from viscoelastic liquid to a viscoelas...